These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 18463402

  • 1. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ.
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
    [Abstract] [Full Text] [Related]

  • 2. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES.
    Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
    [Abstract] [Full Text] [Related]

  • 3. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
    Garwood ER, Kumar AS, Shim V.
    Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
    [Abstract] [Full Text] [Related]

  • 4. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA.
    Cancer; 2004 Oct 01; 101(7):1490-500. PubMed ID: 15378477
    [Abstract] [Full Text] [Related]

  • 5. Statin use and breast cancer: prospective results from the Women's Health Initiative.
    Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT, Women's Health Initiative Research Group.
    J Natl Cancer Inst; 2006 May 17; 98(10):700-7. PubMed ID: 16705124
    [Abstract] [Full Text] [Related]

  • 6. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
    Tewari M, Pradhan S, Singh U, Shukla HS.
    Breast; 2007 Oct 17; 16(5):540-5. PubMed ID: 17587581
    [Abstract] [Full Text] [Related]

  • 7. Statins and breast cancer in postmenopausal women without hormone therapy.
    Eaton M, Eklof J, Beal JR, Sahmoun AE.
    Anticancer Res; 2009 Dec 17; 29(12):5143-8. PubMed ID: 20044629
    [Abstract] [Full Text] [Related]

  • 8. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb 17; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 9. Statins and cancer risk.
    Karp I, Behlouli H, Lelorier J, Pilote L.
    Am J Med; 2008 Apr 17; 121(4):302-9. PubMed ID: 18374689
    [Abstract] [Full Text] [Related]

  • 10. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU, Einarsdóttir K, Friman EI, Wedrén S, Dickman PW, Hall P, Magnusson C.
    Cancer Epidemiol Biomarkers Prev; 2006 Dec 17; 15(12):2482-8. PubMed ID: 17164374
    [Abstract] [Full Text] [Related]

  • 11. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells.
    Mueck AO, Seeger H, Wallwiener D.
    Menopause; 2003 Dec 17; 10(4):332-6. PubMed ID: 12851516
    [Abstract] [Full Text] [Related]

  • 12. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA, Women's Health Initiative Investigators.
    J Natl Cancer Inst; 2007 Nov 21; 99(22):1695-705. PubMed ID: 18000216
    [Abstract] [Full Text] [Related]

  • 13. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S.
    Breast Cancer Res Treat; 2005 Mar 21; 90(1):65-70. PubMed ID: 15770528
    [Abstract] [Full Text] [Related]

  • 14. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P, Chottetanaprasith T, Chatamra K, Sampatanukul P, Wannakrairot P, Rojpornpradit P, Shotelersuk K, Lertbutsayanukul C, Boonjunwetwat D, Vajragupta L.
    J Med Assoc Thai; 2002 Jun 21; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [Abstract] [Full Text] [Related]

  • 15. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M.
    Cytometry B Clin Cytom; 2005 Mar 21; 64(1):43-52. PubMed ID: 15668953
    [Abstract] [Full Text] [Related]

  • 16. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
    Bardia A, Hartmann LC, Vachon CM, Vierkant RA, Wang AH, Olson JE, Sellers TA, Cerhan JR.
    Arch Intern Med; 2005 Mar 21; 166(22):2478-83. PubMed ID: 17159013
    [Abstract] [Full Text] [Related]

  • 17. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
    Jemal A, Ward E, Thun MJ.
    Breast Cancer Res; 2007 Mar 21; 9(3):R28. PubMed ID: 17477859
    [Abstract] [Full Text] [Related]

  • 18. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.
    Breast Cancer Res; 2008 Mar 21; 10(5):R79. PubMed ID: 18808688
    [Abstract] [Full Text] [Related]

  • 19. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA, Hill AG, Houssami N.
    Ann Surg Oncol; 2008 Jul 21; 15(7):1983-8. PubMed ID: 18408976
    [Abstract] [Full Text] [Related]

  • 20. Body weight correlates with mortality in early-stage breast cancer.
    Enger SM, Greif JM, Polikoff J, Press M.
    Arch Surg; 2004 Sep 21; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.